$IMUX
Immunic Inc

2015 Q4 Form 10-Q Financial Statement

#000162828015008337 Filed on November 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.060M $2.690M $2.570M
YoY Change -2.24% 4.67% -14.33%
% of Gross Profit
Research & Development $6.830M $9.646M $10.24M
YoY Change -37.28% -5.84% 66.22%
% of Gross Profit
Depreciation & Amortization $380.0K $325.0K $310.0K
YoY Change 58.33% 4.84% 21.09%
% of Gross Profit
Operating Expenses $9.890M $12.34M $12.81M
YoY Change -29.45% -3.71% 39.77%
Operating Profit -$12.34M -$12.81M
YoY Change -3.71% 39.77%
Interest Expense $20.00K $10.00K $10.00K
YoY Change 100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $10.00K $35.00K $12.00K
YoY Change -83.33% 191.67% -99.45%
Pretax Income -$9.860M -$12.30M -$12.80M
YoY Change -29.37% -3.91% 83.38%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.859M -$12.30M -$12.80M
YoY Change -29.35% -3.89% 83.43%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$13.69M -$20.50M -$23.70M
COMMON SHARES
Basic Shares Outstanding 30.43M shares 24.02M shares 21.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $83.40M $59.80M $79.10M
YoY Change -18.4% -24.4% 153.53%
Cash & Equivalents $83.42M $59.75M $79.09M
Short-Term Investments
Other Short-Term Assets $1.600M $2.900M $3.500M
YoY Change -38.46% -17.14% -16.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $85.09M $62.61M $82.58M
YoY Change -18.82% -24.19% 133.29%
LONG-TERM ASSETS
Property, Plant & Equipment $3.809M $4.163M $2.985M
YoY Change 24.15% 39.46% 24.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $184.0K $171.0K $263.0K
YoY Change -7.07% -34.98% 31.5%
Total Long-Term Assets $3.993M $4.334M $3.248M
YoY Change 22.26% 33.44% 24.92%
TOTAL ASSETS
Total Short-Term Assets $85.09M $62.61M $82.58M
Total Long-Term Assets $3.993M $4.334M $3.248M
Total Assets $89.08M $66.94M $85.83M
YoY Change -17.58% -22.01% 125.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.221M $549.0K $696.0K
YoY Change 5.9% -21.12% -59.06%
Accrued Expenses $5.271M $7.380M $7.530M
YoY Change -40.61% -1.99% 128.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.655M $8.119M $8.498M
YoY Change -35.25% -4.46% 11.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $101.0K $146.0K $283.0K
YoY Change -58.09% -48.41% -29.25%
Total Long-Term Liabilities $101.0K $146.0K $283.0K
YoY Change -58.09% -48.41% -29.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.655M $8.119M $8.498M
Total Long-Term Liabilities $101.0K $146.0K $283.0K
Total Liabilities $6.756M $8.265M $8.781M
YoY Change -35.77% -5.88% 9.76%
SHAREHOLDERS EQUITY
Retained Earnings -$202.9M -$193.0M -$136.9M
YoY Change 34.49% 41.0%
Common Stock $3.000K $2.000K $2.000K
YoY Change 50.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $82.33M $58.68M $77.05M
YoY Change
Total Liabilities & Shareholders Equity $89.08M $66.94M $85.83M
YoY Change -17.58% -22.01% 125.87%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$9.859M -$12.30M -$12.80M
YoY Change -29.35% -3.89% 83.43%
Depreciation, Depletion And Amortization $380.0K $325.0K $310.0K
YoY Change 58.33% 4.84% 21.09%
Cash From Operating Activities -$9.290M -$12.04M -$11.19M
YoY Change -10.67% 7.6% 38.15%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$310.0K -$320.0K
YoY Change 25.0% -3.13% -48.39%
Acquisitions
YoY Change
Other Investing Activities $540.0K $340.0K -$220.0K
YoY Change -485.71% -254.55% -104.49%
Cash From Investing Activities $490.0K $40.00K -$540.0K
YoY Change -372.22% -107.41% -112.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $32.10M
YoY Change -2.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.47M -190.0K -10.00K
YoY Change -3.71% 1800.0% -99.31%
NET CHANGE
Cash From Operating Activities -9.290M -12.04M -11.19M
Cash From Investing Activities 490.0K 40.00K -540.0K
Cash From Financing Activities 32.47M -190.0K -10.00K
Net Change In Cash 23.67M -12.19M -11.74M
YoY Change 2.29% 3.83% 122.35%
FREE CASH FLOW
Cash From Operating Activities -$9.290M -$12.04M -$11.19M
Capital Expenditures -$50.00K -$310.0K -$320.0K
Free Cash Flow -$9.240M -$11.73M -$10.87M
YoY Change -10.81% 7.91% 45.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30425686 shares
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
dei Trading Symbol
TradingSymbol
VTL
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1153000 USD
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
549000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8875000 USD
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7380000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6778000 USD
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7683000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
89000 USD
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
81000 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
248305000 USD
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
251591000 USD
CY2014Q4 us-gaap Assets
Assets
108082000 USD
CY2015Q3 us-gaap Assets
Assets
66943000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
104816000 USD
CY2015Q3 us-gaap Assets Current
AssetsCurrent
62609000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
344000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
492000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-523000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38186000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79091000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102238000 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59754000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
40905000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-42484000 USD
CY2015Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
95.21
CY2015Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250646 shares
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4392617 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23982786 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24145680 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23982786 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24145680 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12798000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33713000 USD
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12307000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42172000 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
110796000 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2014Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1 shares
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
126000 USD
CY2015Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
137000 USD
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
241000 USD
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
146000 USD
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
310000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
853000 USD
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
325000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
947000 USD
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.18
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-7000 USD
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2554000 USD
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1473000 USD
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5500000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M27D
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2566000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7736000 USD
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2689000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9286000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-142000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-397000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3641000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1562000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
406000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000 USD
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000 USD
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
36000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108082000 USD
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66943000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10278000 USD
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8119000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
73195000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-47000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1857000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1769000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-30432000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-40661000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-12798000 USD
us-gaap Net Income Loss
NetIncomeLoss
-33712000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-12300000 USD
us-gaap Net Income Loss
NetIncomeLoss
-42164000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12798000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42866000 USD
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12300000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42164000 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2613000 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
12810000 USD
us-gaap Operating Expenses
OperatingExpenses
36325000 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
12335000 USD
us-gaap Operating Expenses
OperatingExpenses
42231000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12810000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-36325000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12335000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-42231000 USD
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
217000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
652000 USD
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
223000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
692000 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
249000 USD
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
483000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
198000 USD
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
171000 USD
CY2014Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
CY2015Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7000 USD
vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
78000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1365000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2292000 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
250000 USD
CY2015Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
190000 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
986000 USD
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1786000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
55046000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18167000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
241000 USD
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
146000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.08
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
19000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
321000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
274000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9846000 USD
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11846000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3068000 USD
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4163000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10244000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28589000 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9646000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32945000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1592000 USD
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1069000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150833000 USD
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192996000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1765000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2943000 USD
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1057080 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2787059 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
158198 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
195290 shares
vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
70000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.35
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3038336 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.41
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
21.96
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
97563000 USD
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
58678000 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2014Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1545386 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3210693 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3084891 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.54
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.53
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1544310 USD
CY2013Q4 us-gaap Share Price
SharePrice
5.93
CY2014Q1 us-gaap Share Price
SharePrice
11.30
CY2014Q1 us-gaap Share Price
SharePrice
7.55
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1545386 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M22D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
162894 shares
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4410000 USD
CY2015Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2014Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
4744000 USD
CY2015Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0 USD
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0 USD
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21759061 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13483813 shares
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24025481 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23998396 shares
CY2014Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
6072000 USD
CY2015Q3 vtl Accrued Clinical Costs
AccruedClinicalCosts
5424000 USD
vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
410000 USD
vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
110000 USD
vtl Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0 USD
CY2014Q3 vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
0 USD
vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
2600000 USD
CY2015Q3 vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
0 USD
vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
0 USD
vtl Increase Decrease In Other Liabilities
IncreaseDecreaseInOtherLiabilities
169000 USD
vtl Increase Decrease In Other Liabilities
IncreaseDecreaseInOtherLiabilities
-84000 USD
CY2015Q2 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
200000000 USD
CY2015Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
75000000 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedUnderShelfRegistrationStatement
2500000.0 shares
vtl Operating Lease Agreements Expiration Year
OperatingLeaseAgreementsExpirationYear
2017
CY2015Q3 vtl Sale Of Securities Under Public Offerings
SaleOfSecuritiesUnderPublicOfferings
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001628280-15-008337-index-headers.html Edgar Link pending
0001628280-15-008337-index.html Edgar Link pending
0001628280-15-008337.txt Edgar Link pending
0001628280-15-008337-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-20150930.xml Edgar Link completed
vtl-20150930.xsd Edgar Link pending
vtl-20150930_cal.xml Edgar Link unprocessable
vtl-20150930_def.xml Edgar Link unprocessable
vtl-20150930_lab.xml Edgar Link unprocessable
vtl-20150930_pre.xml Edgar Link unprocessable
vtl-93015x10q.htm Edgar Link pending
vtl-93015xexhibit311.htm Edgar Link pending
vtl-93015xexhibit312.htm Edgar Link pending
vtl-93015xexhibit321.htm Edgar Link pending
vtl-93015xexhibit322.htm Edgar Link pending